{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:15:14Z","timestamp":1773332114369,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2744,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:p>Abstract: Few studies have been performed regarding multiple myeloma (MM) in elderly patients. We report a retrospective series of 130 unselected patients with MM aged 75\u2003yr or more at diagnosis. Presenting features were identical to those reported in younger patients, except for a higher rate of infection. Heavy comorbidity was characteristic of unselected geriatric patients. Ninety\u2010four patients received conventional chemotherapy. The response rate was 62%. Treatment toxicity was mild. Median survival was 22 months. Durie\u2013Salmon (DS) clinical stages II and III MM were severe and often led to death, while significantly more patients with DS stage I MM died from unrelated causes (<jats:italic>p<\/jats:italic>&lt;0.0001). Univariate analysis showed that age 85\u2003yr, performance status 2, creatinine level 120\u2003\u00b5mol\/l, beta 2 microglobulin level &gt;4\u2003mg\/l, C\u2010reactive protein level &gt;6\u2003mg\/l, platelet count &lt;100\u00d710<jats:sup>9<\/jats:sup>\/l, presence of infection and lack of response to chemotherapy were adverse prognostic factors for survival. In Cox multivariate regression analysis, age 85\u2003yr (<jats:italic>p<\/jats:italic>&lt;0.0001), performance status 2 (<jats:italic>p<\/jats:italic>&lt;0.0001) and creatinine level 120\u2003\u00b5mol\/l (<jats:italic>p<\/jats:italic>&lt;0.0001) were independent factors in predicting short survival. This study provides evidence that in patients with symptomatic MM age should not be considered as a major obstacle to active treatment. Prospective clinical trials are needed in this population of patients and should include an assessment of quality of life.<\/jats:p>","DOI":"10.1034\/j.1600-0609.2001.00301.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T18:50:32Z","timestamp":1047408632000},"page":"11-17","source":"Crossref","is-referenced-by-count":30,"title":["Multiple myeloma in elderly patients: presenting features and outcome"],"prefix":"10.1111","volume":"66","author":[{"given":"Philippe","family":"Rodon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Linassier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Bernard","family":"Gauvain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotfi","family":"Benboubker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Goupille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Maigre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Luthier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Dugay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Colombat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30341-1"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1577"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198402163100703"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/18.2.330"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1991.tb01856.x"},{"key":"e_1_2_5_7_2","first-page":"729","article-title":"Epidemiologic and age\u2010dependant data on multiple myeloma in Austria","volume":"68","author":"Ludwig H","year":"1982","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90310-9"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/25.5.357"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.77"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900901)66:5<965::AID-CNCR2820660526>3.0.CO;2-M"},{"key":"e_1_2_5_12_2","first-page":"238","article-title":"Multiple myeloma in the elderly: Clinical features and response to treatment in 113 patients","volume":"81","author":"Clavio M","year":"1996","journal-title":"Haematologica"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.8.1227"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(60)90137-5"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_5_16_2","first-page":"145","article-title":"National Cancer Institute proposed guidelines for protocol studies. II. Plasma cell myeloma","volume":"4","author":"Chronic Leukemia\u2013Myeloma Task Force","year":"1973","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_5_18_2","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel N","year":"1966","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox DR","year":"1972","journal-title":"J R Stat Soc B"},{"key":"e_1_2_5_20_2","first-page":"29","article-title":"Multiple myeloma: Review of 869 cases","volume":"50","author":"Kyle RA","year":"1975","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V80.3.733.733","article-title":"C\u2010Reactive protein and serum \u03b22\u2010microglobulin produce a simple and powerful myeloma staging system","volume":"80","author":"Bataille R","year":"1992","journal-title":"Blood"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.5.1774.1774"},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.V83.7.1713.1713","article-title":"Why better prognostic factors for multiple myeloma are needed","volume":"83","author":"Kyle RA","year":"1994","journal-title":"Blood"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1994.tb06866.x"},{"key":"e_1_2_5_25_2","first-page":"273","volume-title":"Myeloma: Biology and Management","author":"Bergsagel DE","year":"1995"},{"key":"e_1_2_5_26_2","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6.633 patients from 27 randomized trials","volume":"16","author":"The Myeloma Trialists' Collaborative Group","year":"1998","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04986.x"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2001.00301.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2001.00301.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0609.2001.00301.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T10:23:49Z","timestamp":1733567029000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0609.2001.00301.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1034\/j.1600-0609.2001.00301.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0609.2001.00301.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}